Work

Phase III Clinical Trials That Integrate Treatment and Biomarker Evaluation

Year: 2013

Type: article

Abstract: Article Tools STATISTICS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2012.48.3826 Journal of Clinical Oncology - published online before print April 8, 2013 PMID: 23569306 Phase III Clinical Trials That Integrate Treatment and Biomarker Evaluation Boris FreidlinxBoris FreidlinSearch for articles by this author , Zhuoxin SunxZhuoxin SunSearch for articles by this author , Robert GrayxRobert GraySearch for articles by this author , Edward L. KornxEdward L. KornSearch for articles by this author Show More Boris Freidlin and Edward L. Korn, National Cancer Institute, Bethesda, MD; and Zhuoxin Sun and Robert Gray, Eastern Cooperative Oncology Group, and Dana-Farber Cancer Institute, Boston, MA. https://doi.org/10.1200/JCO.2012.48.3826 First Page Full Text PDF Figures and Tables © 2013 by American Society of Clinical Oncology

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.48.3826

Authors: Boris Freidlin, Zhuoxin Sun, Robert Gray, Edward L. Korn

Institutions: Eastern Cooperative Oncology Group, Dana-Farber Cancer Institute, National Cancer Institute

Language: English

Topic: Statistical Methods in Clinical Trials

Subfield: Statistics and Probability

Field: Mathematics

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute